Genetic variability in stroke patients: CYP2C19 polymorphisms unraveled.

Area of Science:

• Pharmacogenomics
• Neurology
• Genetics

Background:

• CYP2C19 gene polymorphisms influence drug metabolism, impacting treatment efficacy.
• Stroke patients often receive antiplatelet medications like clopidogrel, which are substrates of CYP2C19.
• Understanding CYP2C19 distribution is crucial for optimizing stroke management in specific populations.

Purpose of the Study:

• To investigate the distribution characteristics of CYP2C19 gene polymorphisms in Han Chinese stroke patients.
• To analyze the relationship between CYP2C19 genotypes and patient demographics or stroke types.
• To identify potential risk factors for clopidogrel resistance in this cohort.

Main Methods:

• Genotyping of 549 Han Chinese stroke patients using PCR and DNA microarray chip technology.
• Analysis of CYP2C19 genotype, allele frequencies, and metabolic types.
• Statistical assessment of correlations with sex, age, infarction type, and clopidogrel resistance.

Main Results:

• Six CYP2C19 genotypes were identified, with *1/*2 being the most prevalent (42.44%).
• No significant associations were found between CYP2C19 distribution and patient sex, age, or stroke infarction type (P > 0.05).
• This study did not identify independent risk factors for clopidogrel resistance.

Conclusions:

• CYP2C19 genotype, allele frequencies, and metabolic types are not correlated with sex, age, or infarction type in Han Chinese stroke patients.
• Common comorbidities like hypertension and dyslipidemia were not statistically associated with CYP2C19 genotypes.
• CYP2C19 genotyping is recommended to guide personalized medication strategies for stroke patients.